EUVIMEDEUVIMED entdecken
Crossref

Complete revascularization for acute coronary syndrome, one step at a time

Tsung-Ying Tsai, Patrick W Serruys

Cardiovascular Research · 2023

DOI: 10.1093/cvr/cvad150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Tsung-Ying Tsai und 1 weiteren Autor:innen. Beteiligte Einrichtung: CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, University Road, Galway H91 TK33, Ireland. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Coronary Artery Disease, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COMPLETE (Complete Versus Culprit-Only Revascularization to Treat Multi-Vessel Disease After Early PCI for STEMI) trial and many other reports ushered in the era of complete revascularization for acute coronary syndrome (ACS) patients without cardiogenic shock.1 However, while the guidelines across the Atlantic endorse complete revascularization, the exact way to do so remained unclear. Open questions remained regarding both the acute and long-term care for these patients. Should patients receive immediate revascularization at the index procedure? Should intermediate (50–70%) lesions in the non-culprit vessels be treated? Should we assess the non-culprit vessels with physiology or intravascular imaging? And what are the roles of pharmacological treatment for the long-term care of these patients to mitigate risks? The BIOVASC (Percutaneous Complete Revascularization Strategies Using Sirolimus-Eluting Biodegradable Polymer-Coated Stents in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease) trial, recently published in the Lancet, is one of the trials to answer the first question regarding the timing of revascularization.2 [The other trial, the MULTISTARS AMI (NCT 03135275), is expected to report its results soon.] In BIOVASC, a prospective, open-label, non-inferiority, randomized trial done in 29 hospitals in Belgium, Italy, the Netherlands, and Spain, 1525 patients with ACS and multi-vessel coronary artery disease (CAD) were randomly assigned to receive either immediate complete revascularization (n = 764) at the index procedure or staged complete revascularization (n = 761) within 6 weeks of the index percutaneous coronary intervention (PCI). An important caveat while reading this trial is that the investigators excluded patients without a clear culprit lesion and patients with chronic total occlusion, which has an incidence of 14 and 20%, respectively.3 Multi-vessel CAD was defined as at least two coronary arteries with a diameter of 2.5≥mm or more and clinically significant (≥70%) stenosis. The authors found that the immediate group was non-inferior to the staged group for the composite primary endpoint of all-cause mortality, myocardial infarction(MI), unplanned ischemia-driven revascularization, and cerebrovascular events at 1 year [hazard ratio (HR) 0.78, 95% CI 0.55–1.11; pnon-inferiority = 0.0011] but was superior at 30 days (HR 0.38, 95% CI 0.22–0.66, psuperiority = 0.0007). This is largely driven by more MI (HR 0.41, 95% CI 0.22–0.76, P = 0.0045) and unplanned ischemia-driven revascularizations (0.61, 0.39–0.95, P = 0.030) for the staged group, which had more early myocardial infarction (MI) than the immediate group [the median time to MI in the immediate group was 235 days (interquartile range 7–301) compared with 16 days (3–74) in the staged group]. In particular, 15(44.1%) of 34 MI occurred in the time window between the index procedure and the staged PCI. In addition, the immediate group received significantly less contrast medium and had a shorter hospital stay, while the stroke, bleeding, and stent thrombosis rates were similar. The authors should be congratulated for conducting this pragmatic study during the COVID-19 pandemic, which showed that immediate revascularization for multi-vessel ACS is safe and feasible. This study demonstrated the encouraging adaptation to radial access but also revealed the low penetration of coronary physiology (fractional flow reserve [FFR] and instantaneous wave-free ratio [iFR]) and intravascular imaging in contemporary European practice. This is an important limitation as both FFR/iFR and intravascular imaging play key roles in answering the unanswered questions about defining and treating non-culprit lesions. Indeed, the fractional flow reserve-guided multivessel angioplasty in myocardial infarction (COMPARE-ACUTE) and complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI3-PRIMULTI) studies showed that complete revascularization using FFR-guided PCI in patients with STEMI and multi-vessel CAD reduced the risk of future events (mainly repeated revascularization) compared with no further invasive intervention after primary PCI.4,5 However, one should be cautious when interpreting the coronary physiology at the time of ACS, as microvascular dysfunction, increased left ventricular end-diastolic pressure, blunted response to adenosine, and increased resting flow may affect the measurement of iFR and FFR. This status of physiologic perturbation can last for 5–7 days or more, and is a function of the size of MI, the amount of the subtended myocardium of the non-culprit vessel as well as the pre-existing microvascular dysfunction of the patient. The unreliability of pressure wire assessment was reflected by the pooled analysis of the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization) and iFR-SWEDEHEART (Instantaneous Wave-Free Ratio vs. Fractional Flow Reserve in Patients With Stable Angina Pectoris or Acute Coronary Syndrome) trials which showed that a clinical presentation with ACS was associated with a higher major adverse cardiovascular event rate compared with chronic coronary syndrome in deferred patients (5.91% vs. 3.64%; P = 0.04).6 On the other hand, the presence of untreated non-culprit vulnerable plaques may contribute to the higher rate of events in these patients. We learned from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree), CLIMA (Relationship between Coronary pLaque morphology of the left anterIor descending artery and long terM clinicAl outcome), and the subanalysis of the COMPLETE trial that ACS patients have a considerable plaque burden in their non-culprit vessels, and these lesions have more vulnerable features.7,8 Interestingly, the vessels with more angiographic stenosis have a higher prevalence of thin-cap fibroatheroma (TCFA) and thinner fibrous caps.9 This may partially explain the findings of the current study and the COMPLETE trial, which rely on visual assessment to decide the target of treatment. However, it is unknown whether pre-emptily sealing these vulnerable plaques with a stent can improve clinical outcomes, and we certainly cannot stent all the lesions in the coronary tree. Currently, the guideline recommends that all patients with ACS should receive high-intensity statin treatment based on the encouraging results from trials that showed the stabilization of vulnerable plaques and the reduction of inflammatory biomarkers after statin treatment.10 In addition, patients who could not achieve the goal of lipid control and those with high Lpa may benefit from treatment with PCSK9 inhibitors or other small molecule drugs. Apart from lipid control, patients with inflammatory activation may probably reap benefits from anti-inflammation therapy such as anti-interleukin-1ß or colchicine. In conclusion, the BIOVASC trial showed us a way forward that prompt treatment for ACS patients with multi-vessel disease is beneficial, but this step forward should be taken with caution, with the guidance of coronary physiology and intravascular imaging and the support of powerful modern pharmacology. There are no new data associated with this article. Biography: Dr. TsungYing Tsai (1989∼) is a Research Fellow/Core Lab Analyst at Corrib Research Centre for Advanced Imaging and Core Laboratory, Clinical Science Institute, and University of Galway, Galway, Ireland. He also holds a position as an interventional cardiologist in the Division of Interventional Cardiology at Taichung Veterans General Hospital, Taichung, Taiwan. He graduated from the Faculty of Medicine, Taipei Medical University, and is currently pursuing his Ph.D. at the University of Galway, Ireland. He has been a university lecturer at the National Yang Ming Jao Tung University, Taipei, Taiwan. He has served as an Adjunct Attending Physician at Taipei Veterans General Hospital and has undergone specialized training in Cardiology and Interventional Cardiology at the same institution. He holds licenses in Internal Medicine, Cardiology, and Interventional Cardiology. He has participated in multiple international conferences, having delivered lectures at events such as EuroPCR 2023, TCTAP 2023, ESC 2023, APHRS 2017, 2018, and 2019 among others. He has contributed to the field with original articles published in well-recognized journals on topics like the effects of particulate matter on cardiac rhythms, cardiovascular imaging, cardiovascular biomarkers, and virtual reality imaging. He has also penned case reports, editorials, and review articles that have added valuable insights to the medical community. Biography: Patrick W. Serruys (1947∼, H-index of 216), is a distinguished interventional cardiologist, imaging expert, and clinical trialist with over four decades of experience in clinical innovation and trials. He has introduced pioneering interventional procedures and devices like BMS, rotablation, coronary physiology, DES, BRS, and TAVI, and has equally advanced cardiovascular imaging, notably quantitative angiography, IVUS, OCT, and multi-slice CT scan. He has been a senior interventional cardiologist since 1979, chief of Interventional Research since 1988, Chief of the Interventional Cardiology department at the Thoraxcenter from 1997 to 2012, and Prof. of Medicine till 1 April 2014 at Erasmus MC in Rotterdam (Netherlands). He is the first-ever chair in interventional cardiology of the Royal Netherlands Academy of Arts and Sciences and was an honorary Professor of Cardiology at the National Heart and Lung Institute (NHLI) of Imperial College, London, until 2021. He is the established Professor of Interventional Medicine and Innovation at the University of Galway, Ireland, and the senior consultant of the CORRIB Research Center for Advanced Imaging and Core Laboratory. Professor Serruys has been a Principal Investigator of more than 90 Multinational trials. He is the author of over 3500 publications in cardiology. Through his reputation, he has attracted young excellent research and clinical investigators and developed large international research projects with them. He has been a promoter of over 99 Ph.D. theses and is the recipient of many awards including Honoris causa doctorates from the University of Athens, the University of Madrid, and the University of Melbourne.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeCoronary Artery DiseasePercutaneous Coronary InterventionST Elevation Myocardial InfarctionHumansTreatment Outcome

Stichwörter der Autor:innen

Acute coronary syndromeComplete revascularizationEarly PCINon-culprit arteryPercutaneous coronary interventionTiming

Autor:innen und Institutionen

  • CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, University Road, Galway H91 TK33, Ireland.
  • Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan.
  • National Heart and Lung Institute, Imperial College London, London, UK.

Zitieren

APA

Tsai, T. Y., & Serruys, P. W. (2023). Complete revascularization for acute coronary syndrome, one step at a time. Cardiovascular Research. https://doi.org/10.1093/cvr/cvad150

Vancouver

Tsai TY, Serruys PW. Complete revascularization for acute coronary syndrome, one step at a time. Cardiovascular Research. 2023. doi:10.1093/cvr/cvad150

BibTeX
@article{Tsai2023,
  author = {Tsai, Tsung-Ying and Serruys, Patrick W},
  title = {Complete revascularization for acute coronary syndrome, one step at a time},
  journal = {Cardiovascular Research},
  year = {2023},
  doi = {10.1093/cvr/cvad150}
}
Kostenlos starten →